CVE-2017-9353

Public Exploit

Description

In Wireshark 2.2.0 to 2.2.6, the IPv6 dissector could crash. This was addressed in epan/dissectors/packet-ipv6.c by validating an IPv6 address.

Category

7.5
CVSS
Severity: High
CVSS 3.0 •
CVSS 2.0 •
EPSS 6.42% Top 10%
Vendor Advisory wireshark.org Vendor Advisory wireshark.org
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
https://bugs.chromium.org/p/oss-fuzz/issues/detail?id=1303 issue tracking third party advisory
http://www.securityfocus.com/bid/98805 vdb entry third party advisory
https://www.exploit-db.com/exploits/42123/ exploit vdb entry third party advisory
https://www.wireshark.org/security/wnpa-sec-2017-33.html vendor advisory
http://www.securitytracker.com/id/1038612 vdb entry third party advisory
https://code.wireshark.org/review/gitweb?p=wireshark.git%3Ba=commit%3Bh=40b2d475c2ad550c1a0f536d5eb30f2a7404c4f0
https://bugs.wireshark.org/bugzilla/show_bug.cgi?id=13675 issue tracking patch vendor advisory

Frequently Asked Questions

What is the severity of CVE-2017-9353?
CVE-2017-9353 has been scored as a high severity vulnerability.
How to fix CVE-2017-9353?
To fix CVE-2017-9353, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2017-9353 being actively exploited in the wild?
It is possible that CVE-2017-9353 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~6% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.